Cargando…

Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach

OBJECTIVE: To investigate willingness to pay (WTP) for treatment with infliximab by patients with ankylosing spondylitis (AS) and explore factors associated with WTP. METHODS: Data from 85 patients participating in the European AS Infliximab Cohort (EASIC) open‐label extension of the AS Study for th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Webers, Casper, Essers, Ivette, van Tubergen, Astrid, Braun, Jürgen, Heldmann, Frank, Baraliakos, Xenofon, Boonen, Annelies
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Ankylosing Spondylitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901401/ https://www.ncbi.nlm.nih.gov/pubmed/28575536 http://dx.doi.org/10.1002/acr.23299

Ejemplares similares

The effect of physical activity and motivation on function in ankylosing spondylitis: A cohort study
por: Brophy, Sinead, et al.
Publicado: (2013)

Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US‐Based Corrona Registry
por: Mease, Philip J., et al.
Publicado: (2018)

Do patients with ankylosing spondylitis adapt to their disease? Evidence from a ‘then-test’ in patients treated with TNF inhibitors
por: Essers, Ivette, et al.
Publicado: (2015)

Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT)
por: Webers, Casper, et al.
Publicado: (2020)

Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study
por: Webers, Casper, et al.
Publicado: (2018)

Depression in ankylosing spondylitis and the role of disease-related and contextual factors: a cross-sectional study
por: Webers, Casper, et al.
Publicado: (2019)

Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction
por: Baraliakos, X, et al.
Publicado: (2016)

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, Xenofon, et al.
Publicado: (2005)

Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years
por: Baraliakos, Xenofon, et al.
Publicado: (2013)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
por: van der Heijde, Désirée, et al.
Publicado: (2019)

New developments in ankylosing spondylitis—status in 2021
por: Klavdianou, Kalliopi, et al.
Publicado: (2021)

Infliximab in the treatment of ankylosing spondylitis
por: Grainger, Rebecca, et al.
Publicado: (2007)

Management of ankylosing spondylitis with infliximab
por: Toussirot, Éric, et al.
Publicado: (2009)

Impact of the COVID-19 pandemic on work productivity in patients with spondyloarthritis: results from the Dutch SpA-Net registry
por: Webers, Casper, et al.
Publicado: (2022)

Erratum to: New developments in Ankylosing spondylitis – Status in 2021
por: Klavdianou, Kalliopi, et al.
Publicado: (2022)

The relationship between inflammation and new bone formation in patients with ankylosing spondylitis
por: Baraliakos, Xenofon, et al.
Publicado: (2008)

Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years
por: Baraliakos, X, et al.
Publicado: (2005)

Correction: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, Xenofon, et al.
Publicado: (2005)

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab
por: Baraliakos, X, et al.
Publicado: (2005)

Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis
por: Ramiro, Sofia, et al.
Publicado: (2015)

Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, X, et al.
Publicado: (2005)

Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
por: Ramiro, Sofia, et al.
Publicado: (2013)

What do we know about co-stimulatory and co-inhibitory immune checkpoint signals in ankylosing spondylitis?
por: Schütz, Christian, et al.
Publicado: (2023)

Phlegmonous gastritis in an ankylosing spondylitis patient treated with infliximab
por: Kim, Bo Young, et al.
Publicado: (2017)

Pleural Tuberculosis following Infliximab Therapy for Ankylosing Spondylitis
por: Krishnan, V. S. Gokul, et al.
Publicado: (2017)

Phlegmonous gastritis in an ankylosing spondylitis patient treated with infliximab
por: Kim, Bo Young, et al.
Publicado: (2017)

Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences?
por: Baraliakos, X, et al.
Publicado: (2015)

Employment and the role of personal factors among patients with ankylosing spondylitis: a Dutch cross-sectional case-control study
por: Webers, Casper, et al.
Publicado: (2018)

A Comprehensive Assessment of Hip Damage in Ankylosing Spondylitis, Especially Early Features
por: Han, Qing, et al.
Publicado: (2021)

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
por: Braun, Jürgen, et al.
Publicado: (2019)

Validation and implementation of a patient-reported experience measure for patients with rheumatoid arthritis and spondyloarthritis in the Netherlands
por: Beckers, Esther, et al.
Publicado: (2020)

Treat-to-target in axial spondyloarthritis: an observational study in daily practice
por: Beckers, Esther, et al.
Publicado: (2021)

Body mass index influences the response to infliximab in ankylosing spondylitis
por: Ottaviani, Sébastien, et al.
Publicado: (2012)

Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis
por: Elalouf, Ofir, et al.
Publicado: (2015)

Bone changes and curative effect of infliximab in patients with ankylosing spondylitis
por: Li, Linying, et al.
Publicado: (2020)

Axial spondyloarthritis including ankylosing spondylitis
por: Braun, Jürgen
Publicado: (2018)

Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1
por: Braun, Jürgen, et al.
Publicado: (2021)

Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
por: Lorenzin, Mariagrazia, et al.
Publicado: (2015)

Effects of etanercept and infliximab on bone metabolism indexes in patients with ankylosing spondylitis
por: Wang, Chenghai, et al.
Publicado: (2020)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
por: Braun, Jürgen, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gg30cbq8ugh62t5vq8o8ubeppr